Literature DB >> 10520943

Course of depression during the initiation of interferon beta-1a treatment for multiple sclerosis.

D C Mohr1, W Likosky, P Dwyer, J Van Der Wende, A C Boudewyn, D E Goodkin.   

Abstract

OBJECTIVE: To examine the hypothesis that increases in depression after initiation of treatment with interferon beta-1a for multiple sclerosis can be explained as representing a return to pretreatment levels of depression.
DESIGN: Level of depression in patients with multiple sclerosis was assessed at 3 time points: 2 weeks before initiation of interferon beta-la treatment, at initiation of treatment, and at 2-month follow-up.
SETTING: A health maintenance organization. PATIENTS: Fifty-six patients with confirmed relapsing forms of multiple sclerosis. MAIN OUTCOME MEASURE: The depression-dejection scale of the Profile of Mood States.
RESULTS: Patients who scored high on the depression measure 2 weeks before the initiation of interferon beta-1a treatment showed significant reduction in depression at the initiation of treatment. However, depression returned nearly to initial levels within 2 months.
CONCLUSIONS: These findings suggest that increases in depression after initiation of interferon beta-1a treatment are related to level of depression 2 weeks before initiation of treatment. Physicians should assess history of depression for all patients in whom interferon beta-1a treatment is initiated. Patients with a recent history of depression are at risk for increased depression within 2 months after starting interferon beta-1a treatment, even though they may not be depressed at the time of treatment initiation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10520943     DOI: 10.1001/archneur.56.10.1263

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  11 in total

1.  Depression levels and interferon treatment in people with multiple sclerosis.

Authors:  Sonya Kim; Frederick W Foley; Mary Ann Picone; June Halper; Vance Zemon
Journal:  Int J MS Care       Date:  2012

Review 2.  Depression in multiple sclerosis: a review.

Authors:  R J Siegert; D A Abernethy
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-04       Impact factor: 10.154

Review 3.  Update on depression in neurologic illness: stroke, epilepsy, and multiple sclerosis.

Authors:  Richard M Sobel; Susan Lotkowski; Steven Mandel
Journal:  Curr Psychiatry Rep       Date:  2005-10       Impact factor: 5.285

4.  Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice.

Authors:  João Carlos Correia de Sa; Laura Airas; Emmanuel Bartholome; Nikolaos Grigoriadis; Heinrich Mattle; Celia Oreja-Guevara; Jonathan O'Riordan; Finn Sellebjerg; Bruno Stankoff; Karl Vass; Agata Walczak; Heinz Wiendl; Bernd C Kieseier
Journal:  Ther Adv Neurol Disord       Date:  2011-05       Impact factor: 6.570

5.  Longitudinal course of depression symptoms in multiple sclerosis.

Authors:  P A Arnett; J J Randolph
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-05       Impact factor: 10.154

6.  Routine depression screening in an MS clinic and its association with provider treatment recommendations and related treatment outcome.

Authors:  L M Stepleman; L M Penwell-Waines; M Rollock; R S Casillas; T Brands; J Campbell; B Ange; J L Waller
Journal:  J Clin Psychol Med Settings       Date:  2014-12

Review 7.  Risk stratification and mitigation multiple sclerosis.

Authors:  Daniel Ontaneda; Samuel Cohn; RobertJ Fox
Journal:  Mult Scler Relat Disord       Date:  2014-09       Impact factor: 4.339

Review 8.  Psychiatric issues in multiple sclerosis.

Authors:  Lydia A Chwastiak; Dawn M Ehde
Journal:  Psychiatr Clin North Am       Date:  2007-12

9.  Effectiveness of glatiramer acetate compared to other multiple sclerosis therapies.

Authors:  Guillermo Izquierdo; Nuria García-Agua Soler; Macarena Rus; Antonio José García-Ruiz
Journal:  Brain Behav       Date:  2015-05-01       Impact factor: 2.708

Review 10.  Neurobehavioral burden of multiple sclerosis with nanotheranostics.

Authors:  Bhasker Sriramoju; Rupinder K Kanwar; Jagat R Kanwar
Journal:  Neuropsychiatr Dis Treat       Date:  2015-10-15       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.